ALX Oncology (ALXO) Fundamental Analysis: Revenue, Earnings & Valuation

5.87 / 10

Netural

Assessment shows moderate fundamentals at 5.9/10. Constructive elements: Asset-MV and Cash-MV, offset by weaknesses in Income tax / Total profit (%) and Gross profit margin (%). Investment case: balanced.

Analysis Checks(7/10)

Revenue-MV

Value-0.18

Score1/3

Weight10.82%

1M Return4.20%

Total operating revenue (YoY growth rate %)

Value142.08

Score3/3

Weight2.96%

1M Return1.27%

Inventory turnover ratio

Value98.02

Score3/3

Weight18.74%

1M Return6.81%

Gross profit margin (%)

Value35.31

Score1/3

Weight-2.24%

1M Return-1.03%

Income tax / Total profit (%)

Value0.00

Score1/3

Weight-0.53%

1M Return-0.24%

Current assets turnover ratio

Value2.32

Score2/3

Weight1.09%

1M Return0.48%

Operating revenue (YoY growth rate %)

Value185.72

Score2/3

Weight0.77%

1M Return0.34%

Cost of sales ratio (%)

Value71.86

Score3/3

Weight8.72%

1M Return3.51%

Asset-MV

Value-0.49

Score3/3

Weight43.79%

1M Return14.53%

Cash-MV

Value0.01

Score2/3

Weight15.87%

1M Return5.85%

Is ALXO undervalued or overvalued?

ALXO scores 5.87/10 on fundamentals and holds a Fair valuation at present. Backed by its -145.70% ROE, 0.00% net margin, -2.54 P/E ratio, 9.93 P/B ratio, and 26.36% earnings growth, these metrics solidify its Netural investment rating.